Teva’s Focus On Its Core Means Increased Outlicensing Action
This article was originally published in The Pink Sheet Daily
Teva’s recent restricting has the firm focusing internal R&D on CNS and respiratory therapies, with plans to out-license or creatively finance development of non-core pipeline assets.
You may also be interested in...
Teva appears to have eased past a management shakeup and extended its lead in Copaxone with the company ready to expand in emerging markets as the next frontier, led by Russia and Latin America.
Teva’s new management has homed in on pain and respiratory disease as two core therapeutic areas. During the firm’s second quarter earnings call, CEO Erez Vigodman gave a sneak peek at his comprehensive portfolio review.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.